Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization

Vaccine
Kirsten KuipersMarien I de Jonge

Abstract

Bacterial outer membrane vesicles (OMVs) are attractive vaccine formulations because they have intrinsic immunostimulatory properties. In principle, heterologous antigens incorporated into OMVs will elicit specific immune responses, especially if presented at the vesicle surface and thus optimally exposed to the immune system. In this study, we explored the feasibility of our recently developed autotransporter Hbp platform, designed to efficiently and simultaneously display multiple antigens at the surface of bacterial OMVs, for vaccine development. Using two Streptococcus pneumoniae proteins as model antigens, we showed that intranasally administered Salmonella OMVs displaying high levels of antigens at the surface induced strong protection in a murine model of pneumococcal colonization, without the need for a mucosal adjuvant. Importantly, reduction in bacterial recovery from the nasal cavity was correlated with local production of antigen-specific IL-17A. Furthermore, the protective efficacy and the production of antigen-specific IL-17A, and local and systemic IgGs, were all improved at increased concentrations of the displayed antigen. This discovery highlights the importance of an adequate antigen expression system for dev...Continue Reading

References

Feb 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·J HessS H Kaufmann
Dec 1, 2001·FEMS Microbiology Letters·S J van DoorenB R Otto
Oct 28, 2003·The Journal of Biological Chemistry·Nicole C Kesty, Meta J Kuehn
Feb 25, 2005·The Journal of Biological Chemistry·Ben R OttoJeremy R H Tame
Oct 27, 2005·JAMA : the Journal of the American Medical Association·Catherine A LexauUNKNOWN Active Bacterial Core Surveillance Team
Feb 17, 2007·Molecular Microbiology·Wouter S P JongJoen Luirink
Nov 21, 2007·PLoS Pathogens·Angela B BrueggemannBernard Beall
Mar 15, 2008·Nature Reviews. Microbiology·Aras KadiogluPeter W Andrew
May 31, 2008·Journal of Molecular Biology·Jae-Young KimMatthew P DeLisa
Jul 22, 2008·Vaccine·Roy RobertsDaniela Hozbor
Sep 20, 2008·PLoS Pathogens·Ying-Jie LuRichard Malley
Nov 13, 2008·Infection and Immunity·Stefan SchildAndrew Camilli
Mar 4, 2010·Microbiology and Molecular Biology Reviews : MMBR·Terri N Ellis, Meta J Kuehn
Feb 16, 2011·Cell Host & Microbe·Kristin L MoffittRichard Malley
Jun 16, 2012·Human Vaccines & Immunotherapeutics·Hellen Amuguni, Saul Tzipori
Jun 16, 2012·Nature Reviews. Immunology·David M Underhill, Helen S Goodridge
Aug 24, 2012·Expert Review of Vaccines·Birgit SimellUNKNOWN Pneumococcal Carriage Group
Feb 19, 2013·Expert Review of Vaccines·Kenny RooseXavier Saelens
Nov 26, 2013·Biochimica Et Biophysica Acta·Peter van UlsenJoen Luirink
Jun 27, 2014·The Journal of Infection·Charles Feldman, Ronald Anderson
Jul 20, 2014·Applied and Environmental Microbiology·Maria H Daleke-SchermerhornJoen Luirink
Nov 16, 2014·Applied and Environmental Microbiology·Anna HjelmJan-Willem de Gier

❮ Previous
Next ❯

Citations

Jan 12, 2016·Human Vaccines & Immunotherapeutics·Alberto GrandiGuido Grandi
Apr 23, 2016·Scientific Reports·Nancy L PriceMario F Feldman
Jun 18, 2017·International Journal of Molecular Sciences·Natalie J Bitto, Maria Kaparakis-Liaskos
Feb 15, 2018·Applied and Environmental Microbiology·H Bart van den Berg van SaparoeaJoen Luirink
Apr 28, 2018·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Sihan WangZhenjia Wang
Aug 8, 2018·FEMS Microbiology Letters·Peter van UlsenJoen Luirink
Jul 19, 2017·Infection and Immunity·Kirsten KuipersMarien I de Jonge
Sep 5, 2017·F1000Research·Courtney E Chandler, Robert K Ernst
Jul 16, 2019·Expert Review of Vaccines·Viviane Maimoni GonçalvesEliane Namie Miyaji
Nov 22, 2019·Biomaterials Science·Ming QinXun Sun
Jul 24, 2020·Journal of Microencapsulation·Jinyan ShiLijiang Chen
May 17, 2018·Frontiers in Cellular and Infection Microbiology·Michael P HaysPhilip R Hardwidge
May 29, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Keman ChengXiao Zhao
Jun 2, 2020·Frontiers in Microbiology·H Bart van den Berg van SaparoeaWouter S P Jong
Jan 10, 2017·Frontiers in Microbiology·André da Silva SantiagoAnete P de Souza
Jan 19, 2019·PeerJ·Yao LeiYongguang Zhang
Jan 10, 2017·Frontiers in Microbiology·Elise S HovinghIlse Jongerius
May 6, 2019·International Journal of Molecular Sciences·Daniel HatlemJack C Leo
Sep 29, 2019·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Linglei JiangRaymond M Schiffelers
Mar 30, 2018·Current Opinion in Biotechnology·Steven FreyRavi S Kane
Mar 29, 2021·Advanced Drug Delivery Reviews·Leila Pourtalebi Jahromi, Gregor Fuhrmann
Apr 27, 2021·Nanomedicine : Nanotechnology, Biology, and Medicine·Yingying GanXin Ding
May 1, 2021·International Journal of Molecular Sciences·Felix BehrensSzandor Simmons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.